Navigation Links
Collegium Pharmaceutical Announces Relocation to Massachusetts
Date:1/17/2013

CANTON, Mass., Jan. 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the relocation of its corporate offices and laboratory facilities to Canton, Massachusetts from Cumberland, Rhode Island.

The Company's lead development program is Oxycodone DETERx® (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx® technology. The Oxycodone DETERx® formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.

Extended-release formulations of opioids (e.g., OxyContin®) are known to be attractive targets for non-medical use since they contain large doses of drug. Crushing these dosage forms can defeat the extended-release properties and result in immediate availability of the opioid, also known as "dose dumping." Crushed formulations are commonly self-administered by abusers orally, intranasally or by IV injection, resulting in a "high." Although marketed formulations carry labels warning against crushing and breaking, there are reports of legitimate pain patients crushing tablets to facilitate swallowing, a practice that significantly increases their risk of serious adverse events.

"We are pleased to have completed our relocation to Massachusetts. The new analytical and development labs will facilitate the completion
'/>"/>

SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
10. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  The investigational S- equol nutritional supplement may ... such as hot flashes, according to a new peer-reviewed ... .[i] "Current data suggest that women may ... symptoms and possibly additional benefits, such as skin health. ... physicians and health care professionals may consider the use ...
(Date:3/30/2015)... MINNEAPOLIS and ORANGEBURG, N.Y., March 30, 2015 ... Inc. (NASDAQ: VSCI ) shareholders have voted ... held today to approve the previously announced agreement ... "We are pleased with the outcome ... to thank both shareholder groups for approving the ...
(Date:3/30/2015)... March 30, 2015 A team of Chinese ... of a cell-surface receptor that plays a critical role ... discloses many new structural features, which challenge the conventional ... and open a new door for future drug discovery. ... on March 30, the researchers at Shanghai Institute ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 2New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 3New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 6
... U.S. Dept. of Defense Continues Study of Copper ... Infections and Improving Indoor Air Quality, NEW ... clinical trails determining the,antimicrobial effectiveness of copper, brass ... Association, announced CDA President Andrew G.,Kireta Sr. ...
... Serious Adverse Reactions, BERKELEY HEIGHTS, N.J., Nov. ... findings from the initial clinical,dosing of G4544, the ... treatment for diseases associated with accelerated bone loss. ... volunteers, has shown good,tolerance with oral bioavailability of ...
Cached Medicine Technology:Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 2Congressional Funds Awarded for Testing of Antimicrobial Copper Metals 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 2Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 3Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 4Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases 5
(Date:3/30/2015)... In a recent report published by SF Gate ... effective drug and alcohol treatment for victims suffering from ... to stabilize the addiction treatment programs, and continue to ... alcohol addiction. Harbor Village Detox is extending its addiction ... in New Jersey, in hopes to help circumvent the ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 This ... the forecast period of 2014 to 2019. , ... tumor ablation market is classified into four major ... (including irreversible electroporation, radio-iodine, HIFU and laser ablation) ... global tumor ablation market is classified into three ...
(Date:3/30/2015)... 2015 Tel-Aviv – March 30, 2015 ... announced the closing of $12.5 million in new financing ... Viola Group. The funding will further GlassesUSA's aggressive business ... in the growing global market of online eyewear, both ... by CEO Daniel Rothman, COO Eldad Rothman, and CTO ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 ... promotion on Invisalign. Eligible patients will receive $200 off ... are not particularly interested in wearing a mouthful of ... team, “The use of traditional braces is effective for ... who are already concerned with their oral appearance. The ...
(Date:3/30/2015)... March 30, 2015 Valerie Harper, the ... sitcoms “Rhoda” and “The Mary Tyler Moore Show,” will ... honoring oncology nurses, CURETM magazine announced today. Harper, who ... the Oncology Nursing Society’s 40th Annual Congress on April ... important role oncology nurses play in the lives of ...
Breaking Medicine News(10 mins):Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3
... cancer in men. More than 218,000 men will be diagnosed ... will die . June is Prostate Cancer Awareness Month, and ... the ways men can keep their prostates healthy and be ... by benign prostatic enlargement affect the vast majority of men ...
... from the US. The latest health supplement and raisins import ... did not meet the Chinese safety standards. Earlier Chinese products ... tainted and dangerous. ,The food inspectors at the ... in products shipped by three American companies. The companies are ...
... patient at the University of Michigan Health System hospital got ... set of lungs. The earlier double lung transplant operation ... along with the doctors slated to perform the operations. ... this transplant and give this man another chance for life, ...
... tea possible in just three seconds. ,Researchers have ... of hot water in only three seconds, reports the Daily Mail. ... tap in the standard way, but the innovation comes when they ... pre-set amount of water 220ml, which is sufficient to fill ...
... study, increasing intake of calcium and vitamin D could reduce ... percent. ,The four-year clinical trial included more ... one of three supplement groups: calcium) plus vitamin D, calcium ... developing cancer was 60 percent lower for those who took ...
... a potential new target, Akt2/PKB, a fat metabolism regulatory protein, ... 2 diabetes. ,The study was conducted by ... the University of Pennsylvania School of Medicine. ,When ... signal the liver to stop forming glucose and burn fat. ...
Cached Medicine News:Health News:Tips to Maintain a Healthy Prostate 2Health News:China Turning Tables on the US on Food Import 2Health News:Transplant Patient Gets a New Lease of Life 2Health News:High Intake of Milk may Reduce Cancer Risks by 60 Percent 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: